Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
Open Access
- 1 July 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (7) , 2060-2069
Abstract
Therapeutic radiation is commonly used in the treatment of squamous cell carcinoma of the oral cavity and pharynx. Despite the proven efficacy of this form of anticancer therapy, high-dose radiation treatment is invariably associated with numerous unwanted side effects. This is particularly true for bone, in which radiation treatment often leads to osteoradionecrosis. The aim of this study was to investigate if treatment with arsenic trioxide (As2O3) could enhance the antitumor effect of radiotherapy whereas minimizing the destructive effects of radiation on bone. As2O3 treatment induced a dose-dependent (1–20 μmol/L) inhibition of endothelial and tumor cell (OSCC-3 and UM-SCC-74A) survival and significantly enhanced radiation-induced endothelial cell and tumor cell death. In contrast, As2O3 treatment (0.5–7.5 μmol/L) induced the proliferation of osteoblasts and also protected osteoblasts against radiation-induced cell death. Furthermore, As2O3 treatment was able to significantly enhance radiation-induced inhibition of endothelial cell tube formation and tumor cell colony formation. To test the effectiveness of As2O3 and radiation treatment in vivo, we used a severe combined immunodeficiency mouse model that has a bone ossicle and tumor growing side by side subcutaneously. Animals treated with As2O3 and radiation showed a significant inhibition of tumor growth, tumor angiogenesis, and tumor metastasis to the lungs as compared with As2O3 treatment or radiation treatment alone. In contrast, As2O3 treatment protected bone ossicles from radiation-induced bone loss. These results suggest a novel strategy to enhance the therapeutic efficacy of radiation treatment while protecting bone from the adverse effects of therapeutic radiation. [Mol Cancer Ther 2008;7(7):2060–9]Keywords
This publication has 31 references indexed in Scilit:
- Bcl-2 Protects Endothelial Cells against γ-Radiation via a Raf-MEK-ERK-Survivin Signaling Pathway That Is Independent of Cytochrome c ReleaseCancer Research, 2007
- Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesisLaboratory Investigation, 2005
- Induction of apoptosis in breast cancer cells by apomine is mediated by caspase and p38 mitogen activated protein kinase activationBiochemical and Biophysical Research Communications, 2005
- Epidemiology of head and neck cancer: Magnitude of the problemCancer and Metastasis Reviews, 2005
- Activation of Pro-apoptotic p38-MAPK Pathway in the Prostate Cancer Cell Line M12 Expressing a Truncated IGF-IRHormone and Metabolic Research, 2003
- Skeletal homeostasis in tissue‐engineered boneJournal of Orthopaedic Research, 2003
- Low Concentrations of Arsenic Induce Vascular Endothelial Growth Factor and Nitric Oxide Release and Stimulate Angiogenesis In VitroChemical Research in Toxicology, 2003
- Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic TrioxideJournal of Biological Chemistry, 2002
- Radiotherapy-Induced Mandibular Bone ComplicationsCancer Treatment Reviews, 2002
- c-Src-dependent Activation of the Epidermal Growth Factor Receptor and Mitogen-activated Protein Kinase Pathway by ArsenicJournal of Biological Chemistry, 2002